SCHEMBL6396398

SCHEMBL6396398

O=C(Cc1cccc(O)c1)c1c(O)cc(O)cc1P(=O)(O)O

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 3/20 0.49
MAPT P10636 5/20 0.46
HPGD P15428 4/20 0.46
MEN1 O00255 3/20 0.46
KMT2A Q03164 3/20 0.46
CYP3A4 P08684 2/20 0.46
MAPK1 P28482 2/20 0.46
PIK3CA P42336 1/20 0.46
GAA P10253 5/20 0.44
ALDH1A1 P00352 2/20 0.43
HSD17B10 Q99714 2/20 0.43
USP2 O75604 1/20 0.43
ALOX15 P16050 1/20 0.43
HTT P42858 1/20 0.43
RAB9A P51151 1/20 0.43
SLC5A1 P13866 2/20 0.42
SLC5A2 P31639 2/20 0.42
PKM P14618 1/20 0.42
CTBP2 P56545 1/20 0.41
CBS P35520 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6404380 0.87 CTBP2 (0.42) LMNAMAPTHPGDMEN1KMT2A
SCHEMBL6403662 0.86 SLC5A1 (0.57) LMNAMAPTHPGDMEN1KMT2A
SCHEMBL27697248 0.85 MAPT (0.60) LMNAMAPTHPGDMEN1KMT2A
SCHEMBL6397103 0.84 CBS (0.53) LMNAMAPTHPGDMEN1KMT2A
SCHEMBL6396380 0.84 MAPT (0.56) LMNAMAPTHPGDMEN1KMT2A
SCHEMBL6395053 0.80 MAPT (0.47) LMNAMAPTHPGDMEN1KMT2A
SCHEMBL6396393 0.80 LMNA (0.46) LMNAMAPTHPGDMEN1KMT2A
SCHEMBL6396972 0.80 ESR1 (0.46) LMNAMAPTHPGDMEN1KMT2A
SCHEMBL6396068 0.77 CTBP2 (0.43) LMNAMAPTHPGDMEN1KMT2A
SCHEMBL6399427 0.76 FFAR1 (0.35) LMNAMAPTMEN1KMT2ACYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050187195-A1 Inhibition of intestinal apical membrane Na/phosphate co-transportation in humans PEERCE BRIAN E (US) 2005-08-25 US disclosed
US-6787528-B2 THERAPY FOR KIDNEY DISEASES BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM 2004-09-07 US disclosed
US-20030162753-A1 Inhibition of intestinal apical membrane Na/phosphate co-transportation in humans BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM 2003-08-28 US disclosed
US-20020133036-A1 Inhibitors of intestinal apical membrane Na/phosphate co-transportation PEERCE BRIAN E (US) 2002-09-19 US disclosed
EP-1175425-A2 INHIBITORS OF INTESTINAL APICAL MEMBRANE NA/PHOSPHATE CO-TRANSPORTATION THE BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) 2002-01-30 EP disclosed
WO-2000043402-A2 INHIBITORS OF INTESTINAL APICAL MEMBRANE NA/PHOSPHATE CO-TRANSPORTATION BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) 2000-07-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050187195-A1 Inhibition of intestinal apical membrane Na/phosphate co-transportation in humans SLC34A3, SLC34A1, SLC34A2 LMNA 4647/4885MAPT 3461/4885HPGD 545/4885
US-20020133036-A1 Inhibitors of intestinal apical membrane Na/phosphate co-transportation SLC10A2, SLC34A3, SLC34A1 LMNA 4664/4885MAPT 3363/4885HPGD 461/4885
US-20030162753-A1 Inhibition of intestinal apical membrane Na/phosphate co-transportation in humans SLC34A3, SLC34A1, SLC34A2 LMNA 4647/4885MAPT 3461/4885HPGD 545/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.